Sep. 14—CARRINGTON, N.D. — When Kacie Rexin first started playing golf, other members of her family might have been able to beat her. "My family introduced me to golf when I was very young and I have ...

San Marino, Calif. - June 17, 2009 - Epeius Biotechnologies (www.epeiusbiotech.com) announced today that its lead product, Rexin-G, has been granted Fast Track designation by the U.S. Food and Drug ...

Phase I study of vorinostat for patients with advanced solid tumors and hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI #8057). Background: Rexin-G (R-G) and Reximmune-C ...

Epeius Biotechnologies Corporation has announced that the Philippine Bureau of Food and Drugs (BFAD) has approved an Expanded Access Program for Rexin-G™, the lead product of Epeius Biotechnologies, ...

Michael Miller, an American businessman from North Carolina, was diagnosed with pancreatic cancer in May 2003. He underwent standard chemotherapy that started in June and continued until January this ...

Prediction of prognosis in hepatocellular carcinoma based on a gene signature from highly tumorigenic liver cancer cells. Background: To evaluate (1) the safety and antitumor activity of Rexin-G, and ...

Epeius Biotechnologies has announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread ...